225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA) which is overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in heavily pre-treated metastatic castration-resistant prostate carcinoma patients. Here we report on treatment outcome and survival using this novel treatment modality in a series of 53 metastatic castration resistant prostate carcinoma patients directly following their androgen deprivation treatment. 225Ac-PSMA-617 was administered to 53 mCRPC patients directly following their androgen deprivation therapy. 68Ga-PSMA PET/CT was obtained at baseline, before every treatment cycle and on follow-up for selection of patients for treatment, to determine the activity to be administered and for response assessment. Serial prostate specific antigen (PSA) was obtained for PSA response assessment.
SATHEKGE Mike;
BRUCHERTSEIFER Frank;
VORSTER Mariza;
LAWAL I;
KNOESEN Otto;
MAHAPANE Johncy;
DAVIS Cindy;
MDLOPHANE Amande;
MAES A;
MOKOALA K;
MATHABE Kgomotso;
VAN DE WIELE C;
MORGENSTERN Alfred;
2022-12-16
SOC NUCLEAR MEDICINE INC
JRC128334
0161-5505 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC128334,
10.2967/jnumed.121.263618 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
